ALCAHEST

As biologist by training, Jürgen holds a PhD in biochemistry from the Eberhard Karls University in Tübingen. During his PhD, Jürgen was employed at Micromet AG (now Amgen) and investigated tumor immunotherapy by IL-2 and GM-CSF antibody cytokine fusion proteins... After his PhD, he joined Roche Diagnostics GmbH as Laboratory Head and Project Leader in the preclinical development of antibodies, bispecific antibodies, antibody drug conjugates and antibody like scaffold fusion proteins. As Principal Scientist he was responsible for the development of biopharmaceuticals within multidisciplinary project teams from early target assessment until identification of a lead candidate for evaluation in phase 1 clinical studies. In 2018, Jürgen joined Morphosys AG as Lab Head Pharmacology and Immuno-Oncology Program Leader in the development of MOR210 (anti-C5aR Mab) enabling a phase 1 trial in collaboration with I-Mab Biopharma. At Morphosys, he was also supporting the preclinical and clinical..

Also known as: Alcahest GmbH, Alcahest Pharma

Primary location: Regensburg Germany